DOCSLIB.ORG

Supplementary Endoscopy Report Form Colorectal Cancer Screening

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplementary Endoscopy Report Form Colorectal Cancer Screening Supplementary Endoscopy Report Form Colorectal Cancer Screening In Patients Treated With Radiation Therapy COLONOSCOPY FORM and PATHOLOGY REPORT Completed by:____________ Date: _____/_____/_____ MRN#: ________________________ Mo Day Year Participant Initials: ___________ Study Id No: ____________________ 1. Record the size, location, type of polyp, and procedures for removal of each polyp. Indicate location of polyp(s) on diagram below using assigned polyp letters. **Note: Assess size using open biopsy forcep** Location Shape Procedure Histology Atypia/Dysplasia CE = Cecum P = Peunculated 1 = Snare polypectomy C = Carcinoma H = High Grade Dysplasia AC = Ascending Colon S = Sessile 2 = Hot biopsy forceps N = Normal L = Low Grade Dysplasia HF = Hepatic Flexure U = Unable to be 3 = Cold biopsy H = Hyperplastic U = Unable to be TC = Transverse Colon determined, not 4 = Not removed T = Tubular determined, not mentioned SF = Splenic Flexure mentioned 5 = Lost/insufficient V = Villous N = None DC = Descending Colon M = Mixed Tubulovillous SC = Sigmoid Colon A = Adenomatous, not specified RE = Rectum U = Unable to be determined, not mentioned O = Other: ________________________________ Polyp Location Distance (cm) Diameter Shape Procedure Histology Atypia Letters from anal verge (mm) A _______ ___________ _______ _______ _______ _______ _______ B _______ ___________ _______ _______ _______ _______ _______ C _______ ___________ _______ _______ _______ _______ _______ D _______ ___________ _______ _______ _______ _______ _______ E _______ ___________ _______ _______ _______ _______ _______ F _______ ___________ _______ _______ _______ _______ _______ G _______ ___________ _______ _______ _______ _______ _______ H _______ ___________ _______ _______ _______ _______ _______ I _______ ___________ _______ _______ _______ _______ _______ J _______ ___________ _______ _______ _______ _______ _______ 1 Supplementary Endoscopy Report Form Colorectal Cancer Screening In Patients Treated With Radiation Therapy COLONOSCOPY FORM and PATHOLOGY REPORT Completed by:____________ Date: _____/_____/_____ MRN#: ________________________ Mo Day Year Participant Initials: ___________ Study Id No: ____________________ Code: 1 = Yes 2 = No 2. Other Results Found During the Procedure ….……………………………..……._____ If Yes: a) Hemorrhoids …………………………….………………………….…………_____ b) Diverticula ……………………………….………………………….……….. _____ c) Chronic inflammation…………………….…………………………………..._____ d) Other, please specify: ___________________________________________ 3. Presence of polyp(s) in distal 60 cm (1 = Yes, 2 = No) ……………..……………_____ 4. Farthest extent reached is: a) If ≤60 cm, farthest extent visualized (cm)..………………….……….……..…_____ If > 60 cm, farthest extent visualized by location: b) Splenic Flexure……………………………………………………….…….…._____ c) Transverse Colon…………………………………………………………..….._____ d) Hepatic Flexure……………………………………….………………………._____ e) Ascending Colon………….…………………………………………………..._____ f) Cecum …..………..……………………………………………………………_____ 2 Supplementary Endoscopy Report Form Colorectal Cancer Screening In Patients Treated With Radiation Therapy COLONOSCOPY FORM and PATHOLOGY REPORT Completed by:____________ Date: _____/_____/_____ MRN#: ________________________ Mo Day Year Participant Initials: ___________ Study Id No: ____________________ Code: 1 = Yes 2 = No 5. Pathology Results a) Lipoma………………………………………………………………………. _____ b) Inflammatory polyp………………………………………………………….._____ c) Juvenile polyp………………………………………………………………..._____ d) Carcinoid tumor…………………………………………………………..……_____ e) Carcinoma……………………………………………………………….……._____ f) Lymphoid hyperplasia………………………………………………..……….._____ g) Other, please specify: _________________________________________________ 6. Presence of adenomatous polyp(s) or cancer (1 = Yes, 2 = No) …………………._____ 7. Total number of adenomatous polyps………………………………………..……_____ 8. Presence of adenomatous polyp(s) or cancer in distal 60 cm (1 = Yes, 2 = No) …_____ Colonoscopist: _______________________________ (Please Print Name) Colonoscopist Signature: _______________________________ P.I. Signature: ______________________________ 3 .
Load more

Recommended publications
  • Juvenile Polyposis Syndrome Might Be
    Gao et al. BMC Gastroenterology (2020) 20:167 https://doi.org/10.1186/s12876-020-01238-7 CASE REPORT Open Access Juvenile polyposis syndrome might be misdiagnosed as familial adenomatous polyposis: a case report and literature review Xian Hua Gao1,2†, Juan Li3†, Zi Ye Zhao1,2†, Xiao Dong Xu1,2,YiQiDu2,4, Hong Li Yan2,5, Lian Jie Liu1*, Chen Guang Bai2,6* and Wei Zhang1,2* Abstract Background: Juvenile polyposis syndrome (JPS) is a rare disorder characterized by the presence of multiple juvenile polyps in the gastrointestinal tract, and germline mutations in SMAD4 or BMPR1A. Due to its rarity and complex clinical manifestation, misdiagnosis often occurs in clinical practice. Case presentation: A 42-year-old man with multiple pedunculated colorectal polyps and concomitant rectal adenocarcinoma was admitted to our hospital. His mother had died of colon cancer. He was diagnosed with familial adenomatous polyposis (FAP) and underwent total proctocolectomy and ileal pouch anal anastomosis. Two polyps were selected for pathological examination. One polyp had cystically dilated glands with slight dysplasia. The other polyp displayed severe dysplasia and was diagnosed as adenoma. Three years later, his 21-year-old son underwent a colonoscopy that revealed more than 50 pedunculated colorectal juvenile polyps. Both patients harbored a germline pathogenic mutation in BMPR1A. Endoscopic resection of all polyps was attempted but failed. Finally, the son received endoscopic resection of polyps in the rectum and sigmoid colon, and laparoscopic subtotal colectomy. Ten polyps were selected for pathological examination. All were revealed to be typical juvenile polyps, with cystically dilated glands filled with mucus.
    [Show full text]
  • Colonic Polyps in Children and Adolescents
    durno_9650.qxd 26/03/2007 12:44 PM Page 233 INVITED REVIEW Colonic polyps in children and adolescents Carol A Durno MSc MD FRCPC CA Durno. Colonic polyps in children and adolescents. Can J Polypes du côlon chez les enfants et les Gastroenterol 2007;21(4):233-239. adolescents Colonic polyps most commonly present with rectal bleeding in chil- Les polypes du côlon se manifestent le plus fréquemment par des saigne- dren. The isolated juvenile polyp is the most frequent kind of polyp ments rectaux chez les enfants. Le polype juvénile isolé est le type de identified in children. ‘Juvenile’ refers to the histological type of polype le plus souvent observé chez les enfants. Précisons qu’ici, le terme polyp and not the age of onset of the polyp. Adolescents and adults « juvénile » fait référence au type histologique du polype et non à l’âge du with multiple juvenile polyps are at a significant risk of intestinal patient au moment de son développement. Les adolescents et les adultes cancer. The challenge for adult and pediatric gastroenterologists is qui présentent des polypes juvéniles multiples sont exposés à un risque determining the precise risk of colorectal cancer in patients with important de cancer de l’intestin. Le défi, pour les gastro-entérologues qui juvenile polyposis syndrome. Attenuated familial adenamatous poly- œuvrent auprès des adultes et des enfants est de déterminer le risque pré- posis (AFAP) can occur either by a mutation at the extreme ends of cis de cancer colorectal chez les patients atteints du syndrome de polypose the adenomatous polyposis coli gene or by biallelic mutations in the juvénile.
    [Show full text]
  • Huge Juvenile Polyps of the Stomach: a Case Report
    Case Report Adv Res Gastroentero Hepatol Volume 6 Issue 3 - July 2017 DOI: 10.19080/ARGH.2017.06.555688 Copyright © All rights are reserved by Tsutomu Nishida Huge Juvenile Polyps of the Stomach: A Case Report Tsutomu Nishida1*, Hirotsugu Saiki1,2, Masashi Yamamoto1, Shiro Hayashi1, Tokuhiro Matsubara1, Sachiko Nakajima1, Masashi Hirota3, Hiroshi Imamura3, Ryoji Kushima4, Shiro Adachi5 and Masami Inada1 1Department of Gastroenterology, Toyonaka Municipal Hospital, Japan 2Department of Gastroenterology, Japan Community Health Care Organization Osaka Hospital, Japan 3Department of Surgery, Toyonaka Municipal Hospital, Japan 4Department of Clinical Laboratory Medicine, Shiga University of Medical Science, Japan 5Department of Pathology, Toyonaka Municipal Hospital, Japan Submission: July 10, 2017; Published: July 18, 2017 *Corresponding author: Tsutomu Nishida, Department of Gastroenterology, Toyonaka municipal Hospital, 4-14-1 Shibahara, Toyonaka, Osaka 560- 8565, Japan, Tel: ; Fax: ; Email: Abstract A 46-year-old man with no familial history of polyposis presented with diarrhea for 2 months. Laboratory data showed anemia, and mild hypoproteinemia. Computed tomography shows two huge tumors in the stomach. Esophagogastroduodenoscopy showed two huge polyps mucosa were partially reddish and had much mucin. All biopsy specimens from the polyps and randomly collected gastric mucosa indicated hyperplasticand giant folds changes. covering Colonoscopy nodular mucosa showed in theseveral stomach. sporadic Chromoendoscopy adenomatous polyps. with indigo We diagnosed carmine showedthe patient that with polyps huge with gastric finger-like hyperplastic villous polys causing protein losing and anemia and sporadic colonic adenomatous polyps. We performed gastrectomy. Immediately after surgery, he stopped diarrhea and recovered hemoglobin and serum protein levels. Histological examinations revealed that hyperplastic glands with cystically dilated glands were separated by abundant connective tissue.
    [Show full text]
  • Hereditary Aspects of Colorectal Cancer Heather Hampel, MS, LGC the Ohio State University
    Hereditary Aspects of Colorectal Cancer Heather Hampel, MS, LGC The Ohio State University Michael J. Hall, MD, MS Fox Chase Cancer Center Learning Objectives 1. Describe Lynch syndrome and identify patients at risk for having Lynch syndrome 2. Recognize other hereditary colorectal cancer syndromes, particularly polyposis conditions 3. Interpret immunohistochemical staining results for the four mismatch repair proteins and other tumor screening test results for Lynch syndrome 4. Understand the difference in cancer surveillance for individuals with Lynch syndrome compared to those in the general population 5. Describe the role of biomarkers (e.g., BRAF, KRAS, NRAS) and MSI-H in predicting response to targeted therapies used for the treatment of CRC CRC = colorectal cancer; MSI-H = microsatellite instability high. Financial Disclosure • Ms. Hampel is the PI of a grant that receives free genetic testing from Myriad Genetics Laboratories, Inc., is on the scientific advisory board for InVitae Genetics and Genome Medical, and has stock in Genome Medical. • Dr. Hall has nothing to disclose. Flowchart for Hereditary Colon Cancer Differential Diagnosis Presence of > 10 polyps Yes No Type of polyps Lynch syndrome Hamartomatous Adenomatous • Peutz-Jeghers syndrome • FAP • Juvenile polyposis • Attenuated FAP • Hereditary mixed polyposis • MUTYH-associated polyposis syndrome • Polymerase proofreading-associated • Serrated polyposis syndrome polyposis • Cowden syndrome FAP = familial adenomatous polyposis. Lynch Syndrome • Over 1.2 million individuals
    [Show full text]
  • Colon Polyps Prepared by Kurt Schaberg
    Colon Polyps Prepared by Kurt Schaberg “Picket fence” nuclei: Elongated, Pencillate, pseudostratified, hyperchromatic Adenoma Nuclei retain basal orientation (bottom 1/2 of cell) Low grade dysplastic changes should involve at least the upper half of the crypts and the luminal surface Tubular Tubulovillous Villous Tubules >75% 25-75% <25% High-grade dysplasia (“carcinoma in situ”) Villi <25% 25-75% >75% Significant cytologic pleomorphism Rounded, heaped-up cells, ↑ nuclear:cytoplasmic ratio Nuclei: “Open” chromatin, prominent nucleoli Lose basal orientation, extend to luminal half of cell Architectural complexity Cribriforming, solid nests, intraluminal necrosis Absence of definite breach of basement membrane Intramucosal Carcinoma Neoplastic cells through basement membrane Into lamina propria but not through muscularis mucosae Single cell infiltration, small and irregular/angulated tubules Marked expansion of back-to-back cribriform glands No metastatic risk (paucity of lymphatics in colonic mucosa) Invasion into submucosa → implied by Desmoplastic response Chromosomal Instability Pathway (most common): APC → KRAS→ p53 (also often β-Catenin and SMAD4) Lynch Microsatellite Instability Pathway: Germline MMR mutation → Loss of heterozygosity → Microsatellite instability Serrated Polyps Hyperplastic polyp (HP): Superficial mucosal outgrowth characterized by elongated crypts lined by nondysplastic epithelium with surface papillary infoldings → serrated luminal contour (like a knife) Sessile serrated lesion (SSL): (formerly sessile serrated
    [Show full text]
  • Pathology Perspective of Colonic Polyposis Syndromes When Are Too Many Polyps Too Many?
    Pathology perspective of colonic polyposis syndromes When are too many polyps too many? David Schaeffer Head and Consultant Pathologist, Department of Pathology and Laboratory Medicine, Vancouver General Hospital Assistant Professor, Department of Pathology and Laboratory Medicine, UBC Pathology Lead, Colon Screening Program Polyposis syndromes in the CSP? Overdiagnosis in Colorectal Cancer Screening? Pathologists’ view of lower GI polyposis Polyposis syndromes with predominately adenomas • Familial adenomatous polyposis • Attenuated familial adenomatous polyposis • MUTYH-associated polyposis • Polymerase proofreading associated polyposis syndrome • Lynch syndrome (rarely) Polyposis syndromes with both adenomas and serrated polyps • Serrated polyposis syndrome • MUTYH-associated polyposis • Hereditary mixed polyposis syndrome • PTEN-hamartoma tumor syndrome Polyposis with predominately hamartomatous polyps • Juvenile polyposis • Peutz-Jeghers Polyposis • PTEN-hamartoma tumor syndrome • Hereditary mixed polyposis syndrome • Cronkhite-Canada syndrome Spectrum of polyps in MAP Guarinos C, et al. Clin Cancer Res. 2014 Mar 1;20(5):1158-68. SSP from patient with MAP Prevalence and Phenotypes of APC and MUTYH mutations in patients with multiple colorectal adenomata Classic polyposis (≥100 adenomas, 1457 pts) • 58% had an APC germline mutation • 6.5% had biallelic MUTYH gerlmine mutations Attenuated polyposis (20-99 adenomas, 3253 pts) • 10% had an APC germline mutation • 7% had biallelic MUTYH germline mutations 10 to 19 adenomas (970 patients)
    [Show full text]
  • Management of Juvenile Polyposis Syndrome in Children
    SOCIETY PAPER Management of Juvenile Polyposis Syndrome in Children and Adolescents: A Position Paper From the ESPGHAN Polyposis Working Group ÃShlomi Cohen, yWarren Hyer, z§Emmanuel Mas, jjMarcus Auth, ôThomas M. Attard, #Johannes Spalinger, yAndrew Latchford, and ÃÃCarol Durno ABSTRACT 02/28/2019 on BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3iUOEA+UwZl4WrbAahuvXsU1ZYmBAUBrDV9S3b4rWUow= by https://journals.lww.com/jpgn from Downloaded Downloaded The European Society for Paediatric Gastroenterology, Hepatology and What Is Known from Nutrition (ESPGHAN) Polyposis Working Group developed recommenda- https://journals.lww.com/jpgn tions to assist clinicians and health care providers with appropriate man- agement of patients with juvenile polyposis. This is the first juvenile There are no prior published guidelines specifically polyposis Position Paper published by ESPGHAN with invited experts. for children at risk, or affected by juvenile polyposis Many of the published studies were descriptive and/or retrospective in syndrome. nature, consequently after incorporating a modified version of the GRADE In paediatric practice, timing of diagnosis, age, and frequency of endoscopy are not standardized, and will by system many of the recommendations are based on expert opinion. This BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3iUOEA+UwZl4WrbAahuvXsU1ZYmBAUBrDV9S3b4rWUow= ESPGHAN Position Paper provides a guide for diagnosis, assessment, and vary across clinicians, and between different countries. management of juvenile polyposis syndrome in children and adolescents, Currently clinical practice is based on case series and and will be helpful in the appropriate management and timing of procedures the clinicians’ personal exposure to juvenile polyposis in children and adolescents. The formation of international collaboration and patients. consortia is proposed to monitor patients prospectively to advance our understanding of juvenile polyposis conditions.
    [Show full text]
  • Juvenile Polyposis Syndrome
    An Introduction to Juvenile Polyposis Syndrome 1 An Introduction to Juvenile Polyposis Syndrome Contents What is Juvenile Polyposis Syndrome (JPS)? 2 What causes JPS? 3 What is the chance of inheriting JPS? 4 How would you know if you have JPS? 5 DNA Analysis 6 Bowel Screening and histological confirmation 8 The gastro-intestinal tract 9 How is JPS treated? 10 What else is a person with JPS more likely to get? 12 2 An Introduction to Juvenile Polyposis Syndrome What is Juvenile Polyposis Syndrome (JPS)? JPS is an inherited condition which mainly affects the stomach and large intestine (also known as the large bowel or colon and rectum). A diagram of the intestine can be found later in this booklet on page 9. People with JPS develop polyps, which are like small cherries on stalks, inside their stomach, colon and rectum. There are many types of polyps but these are called juvenile polyps. The term “juvenile” refers to the type of polyp rather than to the age of the patient when the polyps develop. Most people with JPS have some polyps by the time they are 20 years old. Some may only have three or four polyps over their lifetime, while others may have hundreds. Juvenile polyps often bleed and if they are left untreated may cause anaemia (iron deficiency in the blood). Most juvenile polyps are non-cancerous, however may become cancerous if left untreated. Chromosome 9 Chromosome 18 Chromosome 10 An Introduction to Juvenile Polyposis Syndrome 3 What causes JPS? JPS is a genetic condition, which means it is caused by an altered gene.
    [Show full text]
  • WHO Classification of Tumors of the Central Nervous System
    Appendix A: WHO Classification of Tumors of the Central Nervous System WHO Classification 1979 • Ganglioneuroblastoma • Anaplastic [malignant] gangliocytoma and Zülch KJ (1979) Histological typing of tumours ganglioglioma of the central nervous system. 1st ed. World • Neuroblastoma Health Organization, Geneva • Poorly differentiated and embryonal tumours • Glioblastoma Tumours of Neuroepithelial tissue –– Variants: • Astrocytic tumours –– Glioblastoma with sarcomatous compo- • Astrocytoma nent [mixed glioblastoma and sarcoma] –– fibrillary –– Giant cell glioblastoma –– protoplasmic • Medulloblastoma –– gemistocytic –– Variants: • Pilocytic astrocytoma –– desmoplastic medulloblastoma • Subependymal giant cell astrocytoma [ven- –– medullomyoblastoma tricular tumour of tuberous sclerosis] • Medulloepithelioma • Astroblastoma • Primitive polar spongioblastoma • Anaplastic [malignant] astrocytoma • Gliomatosis cerebri • Oligodendroglial tumours • Oligodendroglioma Tumours of nerve sheath cells • Mixed-oligo-astrocytoma • Neurilemmoma [Schwannoma, neurinoma] • Anaplastic [malignant] oligodendroglioma • Anaplastic [malignant] neurilemmoma [schwan- • Ependymal and choroid plexus tumours noma, neurinoma] • Ependymoma • Neurofibroma –– Myxopapillary • Anaplastic [malignant]neurofibroma [neurofi- –– Papillary brosarcoma, neurogenic sarcoma] –– Subependymoma • Anaplastic [malignant] ependymoma Tumours of meningeal and related tissues • Choroid plexus papilloma • Meningioma • Anaplastic [malignant] choroid plexus papil- –– meningotheliomatous [endotheliomatous,
    [Show full text]
  • Surgery Review Questions
    174 Surgery Review Questions 1. Regarding contrast study for intestinal obstruction: 6. Rightward shift of oxyhemoglobin dissociation (a) Gastrografin is preferred to barium for studying curve occurs with: distal small bowel (a) hypothermia (b) Gastrografin has no therapeutic potential (b) acidosis (c) Gastrografin is less hazardous than barium if (c) decrease in 2,3-diphosphoglycerate aspiration occurs (d) hypocapnia (d) Gastrografin can cause serious fluid shift (e) methemoglobinemia (e) barium can convert partial small bowel obstruc- tion into complete obstruction 7. The most common site of gastrointestinal lym- phoma is: 2. An absolute contraindication to breast-conserving (a) small intestine surgery for breast cancer is: (b) stomach (a) large tumor (c) colon (b) tumor of high grade (d) duodenum (c) early pregnancy (e) appendix (d) retroareolar tumor (e) clinical axillary nodes 8. Meckel’s diverticulum: (a) is a false diverticulum 3. The most common indication for surgery in chronic (b) is asymptomatic in most cases pancreatitis is: (c) commonly presents as gastrointestinal bleeding (a) jaundice in adults (b) pain (d) commonly presents with intestinal obstruction (c) pseudocyst in children (d) gastric outlet obstruction (e) is found in approximately 5% to 10% of people (e) endocrine deficiency 4. The most common cause of spontaneous intestinal 9. Biliary-enteric fistula most commonly connects: fistula is: (a) gallbladder and ileum (a) radiation injury (b) gallbladder and duodenum (b) malignancy (c) common bile duct and jejunum (c) Crohn’s disease (d) gallbladder and jejunum (d) ulcerative colitis (e) common bile duct and ileum (e) diverticular disease 10. Spontaneous closure is least likely in fistulae origi- 5.
    [Show full text]
  • For GI Cancer, a Digital and Molecular Reset
    For GI cancer, a digital and molecular reset Anne Paxton October 2019—You may not be curling up next to the fire with a cup of hot chocolate to read your copy of the new Digestive System Tumours, part of the World Health Organization Classification of Tumours Series. You’re more likely to have it sitting nearby at work with dog-eared pages and a cup of coffee on it, says Ian Cree, MB ChB, PhD, head of the WHO Classification of Tumours Group and editorial board chair of the latest and fifth edition. Still, as essential reference guides in medicine go, the freshly minted 635-page tome, released worldwide in June, is a ravishing picture book. Featuring more than 1,000 high-resolution color graphics, Digestive System Tumours, the first volume of the fifth edition of the WHO series known as the Blue Books, brings a noticeable improvement in image quality and graphic design over the fourth edition, published in 2008. The book’s two-column layout, replacing the former three-column design, allows for enlarged images throughout. And this book is the first to be produced in both a print version and an online subscription version that includes whole-slide imaging. Dr. Washington More important, the book has been rewritten and reorganized to incorporate new tumors, new information about how each tumor behaves, and other significant advances in classification since the 2008 edition. “The new edition was a worldwide, collective project that brought together pathologists from Asia, South America, Europe, North America, Australasia, and Africa to collaborate using the best available evidence and practices,” says Mary Kay Washington, MD, PhD, professor of pathology, microbiology, and immunology at Vanderbilt University Medical Center and a standing member of the WHO series editorial board.
    [Show full text]
  • Paediatric Gastroenterology
    An Atlas of Investigation and Management PAEDIATRIC GASTROENTEROLOGY An Atlas of Investigation and Management PAEDIATRIC GASTROENTEROLOGY José Manuel Moreno Villares, MD Nutrition Unit Department of Paediatrics Hospital Universitario 12 de Octubre Madrid, Spain Isabel Polanco, MD, PhD Professor of Paediatrics Head of Department of Paediatric Gastroenterology and Nutrition Hospital Infantil Univeritario La Paz Facultad de Medicina, Universidad Autónoma Madrid, Spain CLINICAL PUBLISHING OXFORD Clinical Publishing an imprint of Atlas Medical Publishing Ltd Oxford Centre for Innovation Mill Street, Oxford OX2 0JX, UK Tel: +44 1865 811116 Fax: +44 1865 251550 Email: [email protected] Web: www.clinicalpublishing.co.uk Distributed in USA and Canada by: Clinical Publishing 30 Amberwood Parkway Ashland OH 44805 USA Tel: 800-247-6553 (toll free within U.S. and Canada) Fax: 419-281-6883 Email: [email protected] Distributed in UK and Rest of World by: Marston Book Services Ltd PO Box 269 Abingdon Oxon OX14 4YN UK Tel: +44 1235 465500 Fax: +44 1235 465555 Email: [email protected] © Atlas Medical Publishing Ltd 2009 First published 2009 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, without the prior permission in writing of Clinical Publishing or Atlas Medical Publishing Ltd. Although every effort has been made to ensure that all owners of copyright material have been acknowledged in this publication, we would be glad to acknowledge in subsequent reprints or editions any omissions brought to our attention. A catalogue record of this book is available from the British Library ISBN-13 978 1 84692 009 7 The publisher makes no representation, express or implied, that the dosages in this book are correct.
    [Show full text]